Tyra Biosciences, Inc. has announced the initiation and dosing of the first patient in the SURF201 Phase 1 study of TYRA-200, a drug for the treatment of advanced solid tumors with FGFR2 gene alterations. They also provided updates on the SURF301 study of TYRA-300 in oncology and plans for a Phase 2 clinical trial for children with achondroplasia.